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The individual experience of people affected with Long covid (some of them professionals in 
the health system) has allowed us to understand the variability of symptoms that persist 
months after the initial contagion and to have a glimpse of how it affects the function of the 
body. The difficulties that the health system has had in providing an adequate response and 
care for these people, united by the uncertainty of facing an unknown disease, has led them 
to share their experiences through social networks and to organize themselves in groups. 
Some primary care (PC) professionals have collaborated with these groups in order to 
expose the situation and advise them on their process of recognition and care. 
The perseverance of citizen participation in defense of first-hand knowledge experienced as 
a source of knowledge against the imposition of protocols elaborated by experts, and its 
organization in groups has led to the achievement of both local (working with the territorial 
government) and international political incidence (managing to contact institutions such as 
the WHO). 
The coordinated work of professionals and patients has made it possible to develop a joint 
care proposal for people affected with Long covid in PC that facilitates the construction of 
joint knowledge through observation, monitoring and the study of all of those involved. 
  
From individual experience ... 
My infection of SARS-COV-2 and the narrative of my illness 
My contagion occurred the week of March 9, 2020. During that time, I treated five people 
without protective measures in my PC center and also in their homes. They were later 
confirmed cases and hospitalized. 
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The symptoms began after eight days of isolation. I debuted with febrile and respiratory 
symptoms that ended in bilateral pneumonia. Subsequently, for 21 days I presented 
dyspnea at rest with desaturations of 88% at minimal effort and tachypnea, without tolerance 
to sitting. 
Given the importance of the symptoms, I repeatedly went to the emergency services of PC 
and hospitals in my city. However, my previous physical conditions (no pathological 
antecedents of interest), my age (45 years old) and the moderate severity of my symptoms, 
together with the phase of overwhelmed hospitals at the beginning of the pandemic 
prevented me from being hospitalized, despite finding a bilateral lung involvement. 
I overcame bilateral pneumonia without any health support (neither pharmacological nor 
care) in the context of initial uncertainty and confusion in the health system. From that 
moment on, the fear caused by the magnitude of the symptoms and the ignorance about 
their possible evolution would not leave me until many months later. 
I organized my respiratory rehabilitation with bibliographic resources1 and some contacts 
with physiotherapist colleagues when verifying that there were no protocolized recovery 
alternatives at that time for patients like me. After a few days of progressive rehabilitation, I 
decided to return to work 6 weeks after the onset of symptoms, despite persisting fatigue 
and dyspnea on exertion, which I attributed at that time to the usual convalescence process 
in this type of illness. 
Seven days after going back to work, the fever, diarrhea and a disconcerting abdominal 
symptoms returned, which forced me to leave my job again. 
I then started a symptom diary to be able to record all the changes that were taking place in 
my body and that seemed to have no clear pathophysiological explanation (Annex 1). I had 
symptoms that corresponded to almost all systems: polyuria, paresthesia, chest pain, 
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hypotension, erythema, diarrhea, abdominal pain, menstrual disturbances, ageusia, 
headache, loss of concentration, anomia. 
And I was functionally disabled: I could not walk, nor shower or do the usual activities of my 
life without help. I also began to photograph the changes my abdomen was undergoing 
(Annex 2). My abdominal distention magnitude reminded me of those caused by my three 
previous pregnancies. 
My family doctor could not find a convincing explanation for what was happening to me and 
tried to coordinate my care with hospital specialists. However, referrals were not attended to 
because care for hospitalized people was prioritized over patients who had not been 
admitted for months, ignoring the interconsultations requested from PC. 
The first week of May I was affected with abdominal distension, intolerance to eating, 
disabling abdominal pain and more than ten mucus stools a day. After 20 days without being 
able to eat anything, I was admitted to the hospital for study. After 24 hours of observation, I 
was discharged without being able to explain or solve any of the symptoms I presented. My 
disconcerting clinical symptoms were attributed to a situation of anxiety, intervening the 
gender bias in the interpretation of the narrative that I made of my own symptoms in my case 
(as in that of many other affected people)2. I returned home with the certainty that the 
treatment and cure for what happened to me was not going to be provided by the health 
system. People like me who presented persistent symptoms had not been observed or 
studied by the hospitals nor by the primary care centers. I was then convinced that the 
experiences of the people who were suffering from the disease should be integrated into the 
response to face it, as had already happened with other diseases in the past.3 
Thereafter, and for 3 months I tried all the empirical measures and treatments that I was 
reading from other affected people, as well as from colleagues who suggested treatments 
based on the similarity of the new virus with known previous infections. Thus, I took 
paracetamol, metamizole and ibuprofen for pain, montelukast4, azithromycin, corticosteroids 
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and salbutamol for respiratory symptoms, probiotics for diarrhea, famotidine for abdominal 
symptoms, anxiolytics for paresthesias…. 
The pressure of the groups of affected people5 (which we will describe later) led to the 
creation of some specific study units for this type of patients in the infectious services of the 
hospitals in the area6 These units began caring exclusively for people who had been 
hospitalized at the beginning of the pandemic, including later care (in some cases) for 
patients who had not been hospitalized. However, the skepticism and ignorance of the 
majority of health professionals assigned to these units has so far provoked a cascade of 
interventionist actions in the people who have been treated in them, mainly aimed at 
objectifying each symptom referred individually without taking into account the holistic view. 
In my case, between the months of July and August I had an abdominal ultrasound, 
gastroscopy, colonoscopy, digestive biopsies, radiographs, abdominal and thoracic 
tomography, arterial blood gas, blood and urine tests, blood cultures, serologies of different 
viral agents, stool cultures, different studies of intestinal malabsorptive syndromes, blood 
transfusions and intravenous treatments. 
The results of most of the complementary examinations were normal. Only residual 
pulmonary fibrosis and iron deficiency anemia (probably a side effect from my difficulty in 
swallowing) could be observed. 
All this time, my body was still affected and without any other treatment to relieve it than the 
constant support of the people who took care of me (my family and the entire support 
network that was woven around me between friends and professional colleagues). I began 
to discover some actions that improved my physical and emotional state. For example, 
regulating my physical activity, avoiding intellectual effort, controlling stress or adapting my 
intake to the tolerance that my abdomen marked. 
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I learned that the illness, despite involving a disability in many of the facets of my life at that 
time, evolved in the form of flares. These crises, which I called "storms", were unleashed 
without warning, but when they came I was able to clearly identify them. The start of the 
"storm" was always in the morning: I woke up with discomfort and with an inexplicable 
sensation in my body. First it was the headache (which was unlike any previous headache I 
had ever had), and then came the tingling in the arms and legs. At the same time, a low-
grade fever and a disabling fatigue appeared that prevented me from getting out of bed, 
eating, reading, speaking ... I could only lie supine waiting for the crisis to end. The “storms” 
lasted between 3 to 9 days, and later they disappeared just as they had arrived, without me 
being able to identify what had caused their resolution. 
Four months after the infection, I observed that the symptoms in the inter-crisis periods were 
increasingly tolerable and that the disability during the crisis also improved. My last "storm" 
was at the end of July. 
In August I started to improve. The bloating subsided and I was able to reintroduce many 
foods into my diet. Gradually, I regained capacity and tolerance to exercise and established 
a recovery plan that I adapted according to the improvement that my body was experiencing. 
  
... to the collective experience. 
 Co-creation of a protocol with the group of patients affected by Long covid: 
The confusion when faced with unknown symptoms, together with the difficulty of the health 
system to respond to these situations, prompted affected people to organize ourselves into 
groups of7-12. Working groups were created in order to use the media to make the problem 
visible and politically influence the specialized commissions of the government of our 
territory. 
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At the same time, health system professionals observed cases in our PC consultations of 
people who had been infected in the month of March-April who had been classified as mild 
or moderate, who presented persistence in some symptoms and were unable to perform 
daily activities prior to infection. Thus, through social networks we came into contact with 
groups and began to collaborate. 
The collective work has made it possible to promote proposals that can improve the care 
received from the health system, forming a political advocacy group that has been in contact 
with the Secretary of Health Care and Participation of the Department of Health since June, 
2020. Among the achievements of this collaboration is the public recognition by the Council 
of the existence of this type of persistent affectation of COVID19, the creation of an 
informative memo on persistent symptoms sent out to all PC professionals of the Institut 
Català de la Salut13, the creation of a clinical care protocol for PC and the commitment to 
support the research being carried out by PC on the persistent involvement of the disease. 
The collaboration of different groups from different parts of the world has permitted contact 
with the WHO and the recognition of the persistence of symptoms as a distinct entity from 





The appearance of SARS-COV2-19 in PC consultations has transformed the relationship 
between patients and professionals in Spain. 
Since the end of March, 2020, governments have taken measures to prevent infection within 
PC centers by limiting the presence of people requesting care, prioritizing contact by phone 
or online and increasing individual protection for people who work in the health system. 
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However, before the implementation of these measures, many professionals in the health 
system16 had already been infected. Also, among the population there were people affected 
with persistent symptoms more than 3 weeks after contagion (Long covid17). 
In all these people, the impediments of accessing face-to-face care in health centers, the 
lack of knowledge of the persistence of symptoms and the majority of health system 
professionals’ lack of credibility in the symptoms of the patients have contacted them have 
prompted the search for other resources that can provide a response and support for their 
situation. 
This incapacity of the health system, perceived and experienced by affected people, has led 
many of them with persistent symptoms (some also health professionals) to organize into 
groups that expose the problem in order to achieve adequate health care and generate 
knowledge collaboratively18. Thus, in many cases, individualized symptomatology records 
have been made to systematically detail the physical, functional and emotional affectations 
that they were suffering (Annex 1). 
The coordination and collaboration between the group of affected people and some health 
professionals in our territory has crystallized into the joint creation of an protocol of action 
that allows a better approach to the symptoms presented and contributes to the 
simultaneous generation of knowledge in the framework of a co-creative process of citizen 
participation (Annex 3). 
  
Conclusions:  
-    The pandemic has highlighted that a positivist view alone on the disease and its 
evolution is insufficient to create knowledge, and that it is inevitably interwoven with 
the experience of the disease in affected people who, in the face of any disease, and 
especially if it is unknown, are an asset as source of knowledge19. 
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-    Faced with the inefficiencies of the system, the affected groups have been the best 
source of pressure on the administrations by highlighting these inefficiencies and 
demanding a solution for them. Behind the claim for health care, there is a political 
claim. 
-    Present in the claims of those affected is the defense and support of the public health 
system, and specifically PC, which has been reflected in the joint implementation of 
protocols that prioritize listening, observation, longitudinality, an integral vision of the 
person and the role of coordinating care between the different levels of care, the 
values of PC against fragmentation and technification, which the groups of affected 
patients have experienced in other levels of care. 
-    The groups of people affected and affected by persistent COVID call into question 
the current framework for the generation of scientific knowledge. On one hand, they 
cast doubt on the growing obstinacy of the system on the need for tests to define 
diseases (most of them do not have a PCR test that confirms their diagnosis, as 
required by the case definition20, given that in the first months of the pandemic in the 
Spanish State, only PCR was performed on hospitalized patients) and they remind 
clinicians, in an exercise of epistemic justice21 that there is no definition of disease 
without a patient who suffers and narrates it22. On the other hand, they question the 
current classification of the disease, based solely on the severity of the acute period, 
which classifies them as mild or moderate, despite having functional limitations 
beyond the usual recovery period from the acute disease. 
-    The clinical spectrum of covid19 disease with persistent symptoms appears to be 
very broad. It is necessary to promote studies in the primary care setting in order to 
describe all the variability it contains. A study is currently being run on the clinical 
manifestations and their evolution in persistent COVID, with a protocol and 
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questionnaire carried out in collaboration with health professionals and a group of 
affected people. 
-    Health professionals affected by COVID19 represent a fundamental source of 
knowledge, as they have suffered from the deficiencies in the care received from the 
health system in which they usually work. The biologist and hospital-centric 
orientation of said system has been questioned, as it is not able to address the 
uncertainty that has accompanied these people throughout their process of becoming 
ill. 
-    The physical and emotional consequences that these professionals present in the 
future will condition the care they can give their patients. Monitoring will allow us to 
understand the variety and scope of the possible effects of the disease and will 
contribute to formulate mechanistic hypotheses (biologists) that permit finding ways 
of treatment and rehabilitation. 
-    The experience of the clinical descriptions of the patients and the fact that they are 
being shared is very valuable, not only for the understanding of the biological aspects 
of the disease, but also for the understanding of how patients experience symptoms 
and how the health system must learn from them in order to treat COVID (and other 
diseases) in a more holistic way. 
-    Sharing the experience of acquiring knowledge on the persistent symptoms of 
COVID-19   with affected people has enormous potential, not only to improve their 
care, but to raise awareness among medical societies, professional groups, health 
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Introducció 
Els pacients amb símptomes persistents COVID19 representen un problema de salut emergent 
derivat de la infecció per SARS-COV-2.1 La persistència de símptomes invalidants en 
aproximadament el 10% de les persones que han patit la COVID19 molts mesos després de l’inici 
de la clínica condiciona la necessitat de fer un seguiment i una atenció acurada des de les consultes 
d’Atenció Primària.2 Actualment ja s’ha observat, per exemple, la persistència de complicacions 
respiratòries a llarg termini.3 
Cal tenir en compte que les dades existents sobre persistència de símptomes en COVID19 han 
estat realitzades en un entorn hospitalari i en pacients greus que van requerir ingrés a planta o a 
UCI. Els pacients greus representen el 14 % dels infectats.4 No tenim dades de detecció actuals 
que estimin el nombre de persones afectades per símptomes persistents que no van complir criteris 
d’ingrés en el seu moment, que van ser classificats com a lleus o moderats, que van constituir el 
gruix de la primera onada de la pandèmia (81%) i que van ser atesos per l’Atenció Primària. 
Les persones afectades ingressades a l’hospital tenen un diagnòstic de confirmació amb PCR, 
mentre que les persones afectades amb quadres lleus i moderats que no complien criteris d’ingrés 
no tenen prova confirmatòria, ja que la PCR no va estar disponible a l’Atenció Primària fins a 
mitjan mes de maig, moment en què moltes d’aquestes persones ja portaven més de 30 dies 
d’evolució de la malaltia. 
 
1 Carfì A., Bernabei R., Landi F. for the Gemelli Against COVID-19 Post-Acute Care Study Group: 
"Persistent Symptoms in Patients After Acute COVID-19". JAMA. 2020; 324 (6): 603-605. doi: 10.1001 . 
2 Trisha Greenhalgh T., Knight M., A’Court C., Buxton M., Husain L.: "Management of post-acute covid-
19 in primary care." BMJ 2020; 370: m3026. 
3 Fraser, E.: "Long term respiratory complications of covid-19".BMJ 2020; 370: m3001. 
4 Wu Z., MD, McGoogan JM.: "Characteristics of and Important Lessons From the Coronavirus Disease 
2019 (COVID-19) Outbreak in China"; summary of a report of 72.314 cases from the Chinese Center for 
Disease Control and Prevention. JAMA. 2020; 323(13):1239-124.  
Disponible a: https://jamanetwork.com/journals/jama/fullarticle/2762130 
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En el context epidemiològic actual, sense un tractament curatiu conegut fins ara, l’observació i 
l’abordatge de la simptomatologia invalidant en aquestes persones representa una oportunitat per 
a generar coneixement des de l’Atenció Primària juntament amb les persones afectades.  
L’acompanyament d’aquestes persones ha de tenir com objectiu alleugerir-ne el malestar i 
facilitar la seva reincorporació a l’activitat que desenvolupaven abans d’haver estat infectats. 
L’existència d’un protocol d’actuació que fomenti la observació i l’acompanyament d’aquests 
casos es fa imprescindible donada la situació de pandèmia actual, que fa preveure un augment de 
casos de COVID19 en els pròxims mesos, molts dels quals patiran símptomes persistents. 
El protocol d’actuació per al seguiment de persones amb símptomes persistents de COVID19 en 
l’Atenció Primària tindrà com a finalitat: 
Ø Garantir una homogeneïtat en el tractament de la persona amb símptomes persistents, 
amb independència del territori o CAP al qual pertanyi. 
Ø Posicionar el metge de capçalera com a figura de referència en el seguiment i 
tractament integral dels diversos sistemes afectats per la malaltia. 
Ø Millorar l’eficiència de recursos emprats i facilitar l’accés de l’Atenció Primària a 
proves complementàries en base a la clínica particular de cada pacient. 
Ø Aprofitar les sinèrgies creades a partir del coneixement generat per part de les unitats 
postcovid hospitalàries, l’Atenció Primària i el col·lectiu de pacients afectats per 
símptomes persistents. 
Definició 
Persones amb símptomes compatibles amb la COVID19 diagnosticades clínicament durant la 
primera onada de la pandèmia (11 de març 2020-actualitat) amb o sense PCR positiva, amb o 
sense serologia positiva, que presentin símptomes de més de 3 setmanes d’evolució. 5-6 
La manca de disponibilitat de tests durant l’inici de la pandèmia i les seves limitacions fan que 
molts dels i de les pacients que presenten actualment símptomes persistents tinguin els seus 
símptomes desenvolupats en un context de pandèmia com a única prova que avali la seva malaltia. 
Les limitacions de les PCR —falsos negatius més enllà del vuitè dia d’inici de símptomes— i de 
les serologies — s’ha descrit que casos lleus i moderats poden generar menys anticossos o no 
generar-ne — fan que no sigui prudent usar-les com a úniques eines diagnòstiques ni tampoc 
com a definitòries de la curació de la malaltia.7 En aquest cas, com en molts d’altres en la nostra 
pràctica clínica, el diagnòstic s’ha de recolzar principalment en la clínica que presenten i han 
presentat els pacients, en un context de plausibilitat epidemiològica del diagnòstic. 
  
 
5 Welsh Government, NHS Wales, the Scottish Government and NHS Scotland: "COVID Symptom Study". 
United Kingdom Publishing (2020); http://covid.joinzoe.com 
6 Gemelli Against COVID-19 Post-Acute Care Study Group: "Post-COVID-19 global health strategies: the 
need for an interdisciplinary approach"; Aging Clin Exp. Res 2020; doi:10.1007/s40520-020-01616-x. 
pmid:32529595 
7 Bastos ML., Tavaziva G., Kunal Avidi S., et col.: "Diagnostic accuracy of serological tests for covid-19: 
systematic review and meta-analysis." BMJ 2020; 370:m2516Banda. 
J M., Viguruji Singh G, Alser O, Prieto-Alhambra D.: "Long-term patient-reported symptoms of COVID-
19: an analysis of social media data"; medRxiv 2020.07.29.20164418; doi: 
https://doi.org/10.1101/2020.07.29.20164418 
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Seguiment a Atenció Primària 
Els símptomes en les persones amb COVID-19 persistent es caracteritzen per la seva variabilitat 
i l’evolució fluctuant. És per això que el seguiment ha de ser acurat i sistemàtic, amb l’objectiu 
de poder abordar els canvis (i la invalidesa que condicionen en cada pacient) a mesura que aquests 
vagin apareixent. 
- Anamnesi: 
Actualment s’han detallat símptomes en pràcticament tots els sistemes de l’organisme. Caldrà 
orientar l’entrevista clínica recollint els aspectes següents:  
Ø Data d’inici dels símptomes. 
Ø Símptomes actuals 8+9: 
ü Símptomes generals; sensació distèrmica, calfreds, anorèxia, mareig 
ü Símptomes respiratoris; dispnea, tos seca o productiva, sibilàncies 
ü Símptomes musculoesquelètics; fatiga, miàlgies, artràlgies 
ü Símptomes neurològics; cefalea, parestèsies, debilitat, manca de concentració i 
memòria, anòsmia, disgèusia 
ü Símptomes gastrointestinals; disfàgia, pirosi, nàusees, síndrome diarreica 
ü Símptomes cutanis 10; fotosensibilitat, exantemes, sequedat cutània 
ü Símptomes otorrinolaringològics; dolor a sinus, disfonia, vertigen, rinorrea, otàlgia 
ü Símptomes cardiovasculars; canvis en la pressió arterial habitual, palpitacions, 
taquicàrdia 
ü Símptomes oculars: conjuntivitis 
ü Símptomes miccionals 
Ø Diari de símptomes (des de l’inici dels símptomes, si és possible, o des del moment de 
la visita): La realització d’un diari dels símptomes permet una observació més acurada 
de l’evolució de la malaltia i pot ajudar aquestes persones a percebre les millores en el 
temps. En els casos ja establerts i que van iniciar símptomes al mes de març és més 
difícil recollir aquestes dades, ja que hi haurà un biaix de memòria (annex 1). 
Ø Evolució dels relapses o brots: freqüència d’aparició, intensitat (proposem escala 
Likert 0 a 5), símptomes que el constitueixen i ordre d’aparició, situacions que 
l’empitjoren o el milloren, durada del brot, situació postbrot respecte a situació prèvia. 
 
8 Body Politic COVID-19 support group: "What does COVID recovery actually look like? An analysis of 
the prolonged COVID-19 symptoms survey by Patient-Led research team." Disponible a: 
https://docs.google.com/document/d/1KmLkOArlJem-PArnBMbSp-
S_E3OozD47UzvRG4qM5Yk/edit#heading=h.tl7frov254ll 
9 Generalitat de Catalunya (23 de juny 2020); "Coronavirus Sars-Cov 2. Atenció als pacients pot-covid." 
Disponible a: https://canalsalut.gencat.cat/web/.content/_A-Z/C/coronavirus-2019-ncov/material-
divulgatiu/nota-informativa-pacient-post-covid-19.pdf 
10 Galván Casas C., Català A., Carretero Hernández G., et al.: "Classification of the cutaneous 
manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases."; 
Br. J. Dermatol 2020;183:71-7. doi: 10.1111/bjd.19163 pmid: 32348545 
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Ø Escales (annex 2), es proposen les següents escales, aplicables en el diari de símptomes 
que pot realitzar la persona afectada al domicili i en les visites successives de 
seguiment per a poder valorar canvis en el seu estat general. 
ü EVA: escala usada per a la valoració del dolor, autoadministrada de forma diària.  
ü Daniels: escala usada per a avaluar la força muscular, professional, en períodes 
intercrisi (cada mes, p.ex.). 
ü Likert: proposada per a valorar la intensitat dels brots o relapses, 
autoadministrada, en cada brot. 
ü Euroqol-5D: escala de valoració de la qualitat de vida, autoadministrada. Es 
podria utilitzar cada 2 mesos.  
ü Escala Borg modificada: percepció de l’esforç. Determinar amb la persona 
afectada activitats diàries habituals i valorar la percepció de l’esforç en finalitzar-
les (p.ex. baixar les escombraries, pujar un pis d’escales). Autoadministrada. 
Repetir cada mes.  
ü Escala d’Afectació Activitats Vida Diària (AVD): administrada pel o per la 
professional a consulta. Es proposa realitzar-la cada 2 mesos per tal d’objectivar-
ne diferències.  
 
- Exploració física: 
Inicialment cal descartar signes de gravetat que obliguin a fer una derivació al servei d’urgències 
hospitalàries: 2 
Ø Saturació d’oxigen a l’aire <96%. 
Ø Dolor toràcic de característiques inexplicables. 
Ø Empitjorament sensació respiratòria. 
Ø Focalitat neurològica (pèrdua de força en una extremitat, p.ex.). 
Cal una exploració física inicial acurada de tots els i les pacients afectats per COVID19 a consulta 
(o al domicili) que inclogui:  
Ø Presa de constants: temperatura corporal, saturació d’oxigen, tensió arterial, 
freqüència cardíaca. 
Ø Auscultació cardiopulmonar 
Ø Exploració abdominal 
Ø Observació de la pell 
Ø Exploració neurològica 
Ø Valoració de la capacitat funcional i de la qualitat de vida (veure annex 1) 
Posteriorment: 
Ø Es recomana nova exploració física davant de nous símptomes, variacions en els 
símptomes presents i davant de sospita de gravetat. 
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Ø Observació acurada dels símptomes i evolució (veure annex 3). 
 
- Exploracions complementàries: 
Malgrat que no sempre seran necessàries, en cas de detecció d’empitjorament o persistència de 
clínica invalidant cal tenir accés des d’Atenció Primària a: 
Ø Analítica. Valorar segons sospita: dímer-D, LDH, hemograma, ferritina, funció renal, 
electròlits i aquells paràmetres que ens permetin descartar altres processos dins del 
diagnòstic diferencial dels símptomes que presenta la persona que atenem. 
Ø Radiologia de tòrax 
Ø ECG 
Ø Espirometria 
Ø Ecografia pulmonar i abdominal 
Ø Altres proves complementàries en les mateixes condicions d'accés que abans de la 
pandèmia per a aquells casos específics en què estigui indicat un estudi més acurat (per 
exemple: proves d’imatge o endoscòpiques per a valoració de clínica respiratòria o 
digestiva persistent i invalidant, ergometria per a valoració capacitat aeròbica).  
Cal fer èmfasi en l’objectiu de les proves complementàries. Per una banda, poden ajudar a 
descartar gravetat; per altra banda, poden ajudar a objectivar (i, per tant, a reconèixer) allò que la 
persona està experimentant, poden ajudar a reduir la incertesa en el/la pacient i en el/la 
professional (davant d’un resultat dins dels paràmetres de la normalitat) i poden ser útils per a 
descartar altres patologies que es puguin incloure en el diagnòstic diferencial. 
El curs en brots pot fer que sigui útil la realització d’algunes proves durant el brot i durant el 
període intercrisi (en què poden ser normals). 
Cal adequar-les a l’objectiu que perseguim i conversar amb el/la pacient sobre la seva utilitat, 
possibles resultats, etc. per no ser maleficents. 
 
- Coordinació amb segon nivell assistencial: 
És imprescindible la possibilitat de contacte àgil i bidireccional entre professionals (telemàtica, 












Ø Salut mental 
 
- Coordinació amb treball social: 
L’existència de símptomes persistents limitadors o invalidants pot abocar la persona a noves 
dificultats, sobretot les relacionades amb la cura d’altres persones al seu càrrec, amb la seva 
situació laboral i aquelles que en puguin comprometre la subsistència econòmica (alimentària, 
d’habitatge). Aquesta situació derivada de la malaltia no pot recaure únicament sobre l’individu 
que la pateix, sinó que ha d’entendre’s en el context d’una responsabilitat social i comunitària, 
que repari i contribueixi a pal·liar les conseqüències que comporta emmalaltir.11 
Tractament 
En absència d’un tractament curatiu actual, cal oferir a les persones afectades un tractament 
pal·liatiu i simptomàtic amb l’objectiu d’alleugerir el seu malestar. 
El tractament cal que valori les seves necessitats en totes les esferes en les quals hagi impactat la 
malaltia, tal i com es realitza en d’altres afeccions. Les decisions sobre l’abordatge d’aquest 
impacte, s’hauran d’individualitzar i consensuar amb cada pacient. 
 
- Fàrmacs:  
Davant la falta d’evidència sòlida sobre l’eficàcia d’alguns fàrmacs en la millora de símptomes 
de COVID19 però coneixent-la en altres malalties amb símptomes similars, es podrien tractar 
alguns símptomes de forma empírica (com es fa amb altres malalties).  Aquest procés caldrà fer-
lo mitjançant una conversa amb el/la pacient sobre els riscos i beneficis de l’ús de cada fàrmac i 
la incertesa sobre la seva utilització en aquests casos concrets.  
Es pot plantejar l’ús de 12: 
Ø Corticoides orals en tandes curtes per a símptomes respiratoris 
Ø Corticoides tòpics per a alteracions cutànies 
Ø Probiòtics per a afectació intestinal 
Ø Anti-H2 per a afectació gàstrica 
Ø Analgèsics i AINES per a cefalea, dolor muscular, altres dolors 
Pel què fa a l’ús d’antidepressius i benzodiazepines, igual que amb la resta de fàrmacs, cal ser 
prudents i consensuar-ne l’ús i l’objectiu amb les persones afectades. L’ansietat generada per la 
incertesa i per la persistència dels símptomes, per la diferent relació amb el propi cos canviant i 
limitat cal poder-la abordar amb la paraula i l’acompanyament. 
 
11 Castelló M, Fernández de Sanmamed MJ, García J, Mazo MV, Mendive JM, Rico M, Rovira A, Serrano. 
E, Zapater F. Atenció a les persones amb malestar relacionat amb condicionants socials a l’Atenció Primària 
de salut. Barcelona: Fòrum Català d’Atenció Primària, 2016. 




- Rehabilitació:  
Cal poder coordinar-se amb l’equip de rehabilitació de zona des de l’inici del diagnòstic per poder 
oferir rehabilitació respiratòria i física, així com mesures d’adaptació progressiva a l’exercici a 
aquests/es pacients per tal de millorar-ne la funcionalitat de forma gradual.13  
 
- Abordatge del malestar emocional:  
Els efectes que provoquen la persistència perllongada de símptomes en els/les pacients que han 
patit la infecció per COVID19 afecten l’esfera emocional i en condicionen la recuperació.  
El seguiment des d’Atenció Primària ha de garantir el vincle assistencial 13 (coneixement mutu 
entre professional i pacient) que permetrà una escolta activa i empàtica per part del professional 
i evitarà la medicalització innecessària.  
Es podrà valorar de forma individualitzada la prescripció social amb l’objectiu d’utilitzar els 
recursos de suport comunitari en el procés de convalescència, així com la informació sobre 
l’existència d’associacions i col·lectius integrats per persones afectades per símptomes persistents 
de COVID19. 
Finalment, poden ser un recurs adient els grups d’ajuda mútua com espais d'autocura i de  suport 
mutu. 
 
Gestió de la incapacitat laboral 
Donat que actualment no hi ha una definició de “curació” de la malaltia i basant-nos en el que 
coneixem com a “curació” en altres malalties (absència de símptomes), les persones afectades 
per COVID19 amb símptomes persistents no es poden considerar curades en tant que presenten 
símptomes de forma intermitent i una limitació funcional secundària als mateixos, que impedeix 
que es reincorporin a la seva activitat laboral.14  
Cal avaluar l’adequació del manteniment de la baixa en les visites successives de seguiment i en 
tant que continuïn amb símptomes. 
  
 
13 Royal College of Occupational Therapists; "How to manage post-viral fatigue after COVID-19? Practical 
advice for people who have recovered at home."; Disponible a: https://www.rcot.co.uk/how-manage-post-
viral-fatigue-after-covid-19-0 
14 Alwan, Nisreen A.: "Surveillance is underestimating the burden of the COVID19 pandemics."; 
Correspondence; The Lancet. Disponible a: DOI: https://doi.org/10.1016/S0140-6736(20)31823-7 
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ANNEX 1 
Diari d’evolució dels símptomes amb ús d’escales per valorar-ne intensitat: 
 DIES i EVOLUCIÓ (durant un mes)    
SÍMPTOMES  
I ESCALES 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 18 20 21 22 23 24 25 26 27 28 29 30 31 
Tos                                
Fatiga                                
Febreta                                
altres 
 
                               
.../...                                
.../...                                
                                
                                
                                
                                
                                
                                
                                
                                
E. EVA 
(dolor) 
                               
E. Daniels 
(força) 
                               
Likert 
(brot) 










                               
E. AVD                                 
 
ANNEX 2 
Proposta d’escales d’avaluació: 
Se suggereix l’ús d’algunes escales per poder avaluar el seguiment d’una forma que permeti 
comparar l’evolució dels símptomes. 
 
- EVA 





Avaluació de la intensitat dels brots: 
 
1 Molt suportable 
2 Poc suportable 
3 Suportable 
4 Força insuportable 
5 Insuportable 
 
- Escala Daniels 
Avaluació de la força muscular: 
0 - Absència de contracció 
1 - Contracció sense moviments 
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2 - Moviment que no venç la gravetat 
3 - Moviment complet que venç la gravetat 
4 - Moviment amb resistència parcial 
5 - Moviment amb resistència màxima 
- Escala Borg modificada d’esforç percebut 
Escala senzilla que permet avaluar la progressió en l’esforç percebut per part del/la pacient, 
aplicable a la realització de tasques diàries. Usada en rehabilitació cardiovascular, pulmonar i en 
entrenaments: 
 
0 - Repòs 
1 - Molt, molt lleuger 
2 - Molt lleuger 
3 - Lleuger 
4 - Una mica pesat 
5 - Pesat 
6 - Més pesat 
7 - Molt pesat 
8 - Molt molt pesat 
9 - Màxim 
10 - Extrem 
 
- Taula d’Afectació d’Activitats de la Vida Diària (AVD) 15: 
Categories d'Afectació de les Activitats de 
la Vida Diària (AVD) 
Grau d’Afectació d’Activitats de la Vida 
Diària (AVD) 
Sense afectació Les funcions són normals  
Afectació lleu  Presenta dificultats en activitats específiques, 
però pot realitzar-les 
 
15 ídem nota 13: Royal College of Occupational Therapists; "How to manage post-viral fatigue after 
COVID-19? Practical advice for people who have recovered at home."; Disponible a: 
https://www.rcot.co.uk/how-manage-post-viral-fatigue-after-covid-19-0 
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Afectació moderada  Pot realitzar activitats específiques amb esforç 
i malestar 
Afectació severa  Necessita ajuda per a la realització d’activitats 
Afectació molt severa Impossibilitat per a realitzar les activitats 
- EUROQOL-5D (requereix credencials per usar-la): 
Marcar amb una creu la resposta de cada apartat que descrigui millor el seu estat de salut a dia 
d’avui: 
Mobilitat 
No tinc problemes per caminar   □ 
Tinc alguns problemes per caminar    □ 
Haig d’estar al llit    □ 
 
Cura personal: 
No tinc problemes per a la cura personal   □ 
Tinc alguns problemes per dutxar-me o vestir-me   □ 
Soc incapaç de dutxar-me o vestir-me   □ 
 
Activitats quotidianes (p.ex. treballar, estudiar, fer les tasques de la casa, activitats familiars 
o activitats en el temps de lleure): 
No tinc problemes per a realitzar les meves activitats quotidianes   □ 
Tinc alguns problemes per a realitzar les meves activitats quotidianes   □ 
Soc incapaç de realitzar les meves activitats quotidianes   □ 
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Dolor/malestar: 
No tinc dolor ni malestar              □ 
Tinc dolor o malestar moderat    □ 
Tinc molt de dolor o malestar      □ 
 
Ansietat/depressió: 
No estic ansiós/osa ni deprimit/da     □ 
Estic moderadament ansiós/osa i deprimit/da     □ 








Taula 1: Símptomes observats en pacients amb símptomes persistents COVID19 
A fi de facilitar l’anamnesi i la recollida de dades, i donada l’enorme variabilitat, es presenten 
els símptomes agrupats per sistemes tot i que en el moment actual es desconeix si els símptomes 
referits poden ser atribuïbles o no al sistema assignat. 
 
Símptomes generals Malestar i fatiga R53 
Febre o febreta R50.9 
Dolor a les articulacions M25.5 
Tinnitus H93.1 
Pèrdua de pes  
Símptomes respiratoris Dispnea R06.0 
Tos R05 
Afonia/ disfonia R49.1 
Inspiració incompleta  
Epistaxi  
Congestió nasal/mucositat  
Diagnòstics respiratoris Pneumònia viral J12.9 
Embolisme pulmonar I26 





Elevació tensió arterial (sense 
diagnòstic d’HTA) 
R03.0 
Símptomes neurològics Insomni G47 







Altres signes i símptomes relacionats 
amb la funció cognitiva 
R94.1 
Parestèsies  
Trastorn del sistema nerviós 
autònom 
G90.9 
Símptomes dermatològics Prurit L29.9 
Rash o erupció cutània R.21 
Caiguda del cabell  
Aftes bucals, herpes labial  
Símptomes digestius Nàusees/ vomits R11 
Anorèxia/ inapetència  
Diarrea  
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Presència de sang o mucositat en la 
femta 
 
Distensió abdominal  
Altres Alteracions visuals no especificades H53.9 
Poliúria  
Alteracions del cicle menstrual  
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MANAGEMENT OF PEOPLE WITH COVID-19 AND LONG-LASTING SYMPTOMS IN PRIMARY 




Patients presenting long-lasting symptoms of COVID-19 represent an emergent Health issue 
derived from SARS-COV-21 infection. 
 
The persistence of invaliding symptoms affects approximately 10%2  of people who have 
suffered COVID-19 months after the onset of the acute disease. It determines the need of a 
caring follow-up from primary care consultations. For example, there have been described 
long-term respiratory complications3 .  
 
Data about the long-lasting symptoms of COVID19 has been reported from hospital settings 
and in severe patients, who had been admitted either to hospital or to an Intensive Care Unit. 
Severe patients represent 14% of infected patients. Evidence is lacking about estimated data of 
the number of people affected by long-lasting symptoms who didn’t fulfil admission criteria at 
the moment of acute disease and were classified as a mild or moderate. They constitute the 
huge of the first wave of the pandemic (81%) and were assisted by primary care centres.  
People admitted to the hospital have a PCR confirmation test whereas people with mild or 
moderate disease who didn’t fulfil admission criteria don’t have, due to the lack of availability 
of the confirmatory test (PCR) at the primary care Health centres until may 2020. At that 
moment, many of these people were experimenting symptoms from more than 30 days.   
 
In the actual epidemiologic context, without any curative treatment, observation and 
management of invalidating symptoms presented by these patients represents an opportunity 
to generate knowledge from primary care in collaboration with people affected. The objective 
of accompanying these people has to be alleviate their physical and emotional discomfort and 
facilitate the reincorporation to their laboral and personal activity which they developed 
before getting sick.   
 
The existence of a guidance that encourage observation and accompaniment of these people 
is essential given the actual pandemic situation, with an expected increase of COVID19 cases 
during next months, some of them will develop long-lasting symptoms as we now have 
observed.  
 
The object of this guidance aims to be:   
 
● To guarantee a similar treatment of people with long-lasting symptoms, no matter 
where they live or the Health centre they are related to.  
● To position the primary care professional as person of reference for the management, 
follow-up and integral treatment of people with long-lasting symptoms and their 
different affected systems.  
● To improve the efficiency of the used resources, giving primary care access to any test 
required based on the particular clinical situation of every patient.  
● To take profit of the joint effort created through the generated knowledge of Post-
Covid Units at the hospitals with primary care and the group of patients affected with 




People with compatible symptoms of COVID19 who have been clinically diagnosed during the 
first wave of pandemic (11th march 2020- to actuality) with or without a positive PCR, with or 
without a positive serology, who presents symptoms for more than 3 weeks5-6  from the onset.  
 
Lack of availability of tests at the beginning of the pandemic and their limitations, implies that 
the vast majority of people with long-lasting symptoms have as the only aval of their disease, 
their symptoms, which they developed in the ongoing of a pandemic.  
 
PCR limitations (false-negative results beyond 8th day of symptoms onset) and serologies 
limitations (mild and moderate cases have been described to generate few or none 
antibodies7) make imprudent using them as the only diagnostic nor defining tool of disease’s 
curation7. 
In this cases, as in many cases we face in our daily practice, diagnosis has to rely on the clinical 
features that have experienced or that are experiencing patients, in a context of epidemiologic 
plausibility for that diagnosis.   
 
- FOLLOW-UP AT PRIMARY CARE 
 
Prolonged symptoms in people with COVID19 are characterized by their variability and 
fluctuant evolution. That is way the following up have to be accurate and systematic with the 
aim of describing and tackling the changes (and the disability that these symptoms condition in 
each patient), as they occur.  
 
ANAMNESIS:  
Symptoms have been described in practically all systems. Medical record may be oriented to 
collect the following aspects:  
 
● Day of symptoms ‘onset.  
● Actual symptoms8-9:  
 
○ General symptoms: feeling feverish, chills, anorexia, dizziness  
○ Respiratory symptoms: dyspnoea, wheezing, dry or expectorated cough 
○  Muscle-skeletal symptoms: fatigue, myalgia, joint paint  
○ Neurologic symptoms: headache, paraesthesia, weakness, lack of memory and 
concentration,  anosmia and dysgeusia  
○ Gastrointestinal symptoms: dysphagia, heartburn, feeling nauseous, diarrhoea. 
○ Cutaneous symptoms9; photosensitivity, rashes, dry skin.   
○ Otorhinolaryngologic symptoms: sinus pain, dysphonia, vertigo, nasal 
discharge, earache  
○  Cardiovascular symptoms: blood pressure changes, palpitations, tachycardia  
○ Ocular symptoms: conjunctivitis  
○ Urinary symptoms  
 
● Diary of symptoms (from the onset of symptoms, if it is possible, or from the moment 
of the first appointment). Creating a symptoms’ diary allows an accurate observation 
of the disease and can help people affected to perceive improvement as time goes by.   
In people who started symptoms during March, the memory bias can difficult data 
collection. (annex 1) 
 
● Relapse or flair-up evolution and description: frequency, intensity (we propose using 
Likert Scale from 0 to 5), which symptoms includes and order of appearance, which 
situations make them better or worse, duration of the episode, functional situation 
after the relapse compared to previous situation.  
 
- Scales (annexe 2). The following scales are proposed, as they can be useful to specify 
the intensity or quality of some of the symptoms in the diary;  they can be completed 
by the affected person at home and discussed at following encounters with the 
primary care physician, aiming to detect changes in their functional state.    
- EVA : Used to value pain, autocompleted diary.   
- Daniels : Scale used to assess muscle strength. Completed by a physician, 
during inter-relapses periods (monthly).  
- Likert : A proposal for quantify the intensity of relapses or flair-ups, 
autocompleted, used at each relapse. 
- Euroqol-5D : Value of quality of life, autocompleted. It could be used each 2 
months.  
- Modified Borg scale: It values the effort perception. It needs to previously 
select with affected person some repeated daily activities and assess the effort 
of doing them when ending. E.g. to take trash out, to climb one floor by the 
stairs). AutoCompleted, monthly.   
- Activities of Daily Living (ADL) Scale: Complemented by primary care physician 
or nurse at the Health centre. It is proposed to completed it each two months, 





Initially, to discard severity signs that implies a referral to an emergency room is needed2 : 
- Oxygen saturation at room air <96% 
- Inexplicable causes of chest pain 
- Worsening of a respiratory discomfort 
- Neurological focus (loss of strength in any upper or lower limbs, e.g) 
 
It is essential to do an accurate initial physical exploration of every patient affected with 
COVID19 either at the Health centre or at home, including:  
● Vital signs: temperature, oxygen saturation, blood pressure, heart rate.  
● Cardio-pulmonary auscultation 
● Abdominal exploration 
● Skin inspection 
● Neurological exploration 
● To assess functional capacity and quality of life (see annex 1) 
 
Afterwards:  
o It is recommended a new physical exploration in front of the appearance of 
new symptoms, changes or variation in existing symptoms or if severity is 
suspected.  
o A thorough observation of symptoms and their evolution (see annex 3) 
 
 
ADDITIONAL TESTS   
Although they will not always been necessary, in case of worsening or long-lasting disabling 
symptoms, primary care needs to have a quick access to:  
o Blood test: depending on suspicion: LDH, hemogram, CBC, dímer-D, LDH, 
hemogram, ferritin, kidney function, electrolyte and all those values that helps 
us to discard other pathologies involved in the differential diagnosis of 
symptoms presented.  
o Chest X-ray 
o Electrocardiogram 
o Functional respiratory test  
o Pulmonary and abdominal sonography 
o Other kind of tests easily to access and perform at equal conditions than 
before pandemic, for those specific cases which need an thorough study (e.g. a 
tomography or an endoscopy to value respiratory symptoms or persistent and 
disabling digestive symptoms; cardiac stress test to assess aerobic ability)  
 
 
It is important to insist on the aim of additional tests. On one hand, they can help to discard 
severity, on the other hand they can help to objectify (and so, to recognize) what is happening 
to the affected person, they can also reduce uncertainty both in the patient and professional 
(in front of a non pathologic result of the test) and can be useful to discard other pathologies 
included in the differential diagnosis.  
 
The relapsing course of long COVID19 could make the performance of additional test as useful  
during the flair-up as during the inter-relapses period (when the result is more likely to be 
normal).   
 
We need to adequate the aim we prosecute with the test and have a conversation with the 
patient about its usefulness, probable results, interpretations of the results, e.g., just to avoid 
being maleficient.  
 
OTHER SPECIALIST REFERRAL 
An agile and bidirectional contact is essential between primary care professionals and hospital 
specialists, by phone, by an interconsultation without patient, by videoconference or whatever 






▪ Physical Therapist or Occupational Therapist 
▪ Ear, nose and throat specialist 
▪ Rheumatologist 
▪ Endocrinologist 
▪ Mental Health specialists  
 
SOCIAL WORKER COORDINATION. 
As prolonged symptoms can be disabling, people can experience new difficulties, among them 
those related with taking care of people at their charge, their Laboral situation and others that 
can compromise their economic survival (nutritional, housing). This situation caused by the 
disease can’t rely only on individuals who suffer from it, but must be understood in the context 
of a social and communitarian responsibility, which has to be able to help them and repair the 




There is no curative treatment, but in its absence, we can offer the affected people a palliative 
and symptomatic treatment with the aim of alleviate their malaise.  
Treatment must value their needing’s in every sphere where disease might have impacted, as 
we do in front of other diseases. Decisions about the management of this impact, must be 
individualized and agreed with each patient.  
 
Drugs:  
In front of lacking of evidence of efficacy of some drugs to improve COVID19 symptoms, but, 
knowing their usefulness in other diseases that develop similar symptoms, some of them can 
be empirically treated, as we do in other diseases. Prescribing drugs to patients needs to be 
done in a conversation with patient informing about risks and benefits of using each of the 
proposed drugs, uncertainty involving their use in particular cases.   
 
Drugs that may be useful can be11: 
- Oral steroids, for respiratory symptoms.  
- Topic steroids for skin conditions 
- Probiotics if there is intestinal involvement.  
- Anti-H2 if gastric involvement. 
- Analgesia and NSAID if headache, muscular pain and other kind of pain. 
 
Use of antidepressants and benzodiazepines ((and the aim we pursued with it),  as prescription 
of other drugs does, must be agreed with the patient and demands to be cautious. Anxiety can 
be generated by uncertainty, by persistence of symptoms, by a different relationship with 
oneself and a body that changes uncontrollably and by feeling disabled. This anxiety must be 
managed principally with words and accompaniment.   
 
Physical Therapy:  
A coordination with the Physical Therapy Centres of each area from the beginning of diagnosis 
in order to offer physical and respiratory therapy, and also progressive exertion adaptation in 
those patients is needed to improve gradually their funcionality 12.  
 
Management of emotional distress:  
Emotional effects of the prolonged symptoms in patients with COVID19 can condition their 
recovery.  
Primary Care follow-up has to be able to guarantee the bond13  that exists between patient and 
professional. Its existence will allow an active and empathic listening by the professional and 
will reduce unnecessary medicalization.  
Some patients will need social prescription with the aim to use community support resources 
during their convalescence and information about the existence of associations and other 
groups of people affected by prolonged symptoms of COVID19.  
Finally, some mutual helping groups as self-cure and mutual support spaces can be an useful 
resource for some patients.  
 
 
MANAGING LONG TERM DISABILITY.  
As there is not a definition for “curation”14 of COVID19 and based on what we know about 
“curation” in other diseases (absence of symptoms), people affected with prolonged 
symptoms of COVID19 can’t  be addressed as “cured” because they still experiencing 
intermittent symptoms and a functional disability secondary to those symptoms that prevent 
them from going back to their work.  
An evaluation of maintenance of the long term disability has to be done in each follow-up 
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